Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ABVC vs AQB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABVC Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 4–2 Matrix Metrics)

ABVC Overall Winner 6-Pillar Tally: ABVC 5 – 0 AQB (1 Tie) Matrix Metrics: ABVC 4 – 2 AQB

As of Nov 17, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over AquaBounty Technologies, Inc. (AQB) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABVC carries a Unified Composite Score of 34.2/100 (SELL) at $0.94 (N/M Forward P/E, 0.0% operating margin), whereas AQB carries 44.6/100 (HOLD) at $0.82 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AQB currently prints a higher short-term Unified Composite Score (44.6/100 HOLD vs. ABVC 34.2/100 SELL), ABVC captures the overall institutional head-to-head verdict (4–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+104.5% vs. -93.5% YoY).
  • Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.3); meanwhile AQB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABVC vs AQB
ABVC NASDAQ Head-to-Head Winner
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.94
+0.0% 1D
Market Cap $24.8M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.34β · 53% Vol
Unified Composite Score
34.2 / 100 SELL
Tech 15.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.3 · SMA20: $1.00 · SMA50: $1.02
AQB NASDAQ
AquaBounty Technologies, Inc.
Fishing, Hunting And Trapping
$0.82
+2.01% 1D
Market Cap $9.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.93β · 117% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 33.0 Fund 49.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.5%), weak momentum, RSI 37
RSI-14: 37.5 · SMA20: $1.04 · SMA50: $1.03

6-Pillar Scorecard Institutional Category Breakdown (ABVC 5 – 0 AQB)

Columns: Metric · ABVC · AQB
1. Valuation Multiples ABVC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 31.1x N/M
2. Growth & Scale ABVC
Revenue Growth (YoY) +104.5% -93.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $797,916 N/A
Market Cap $24.8M $9.7M
3. Profitability & Quality ABVC
Gross Margin 100.0% N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -52.7% -68.9%
4. Balance Sheet & Cash Flow ABVC
Cash Generation (TTM) -$5.8M EBITDA -$7.2M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.49 Book/Sh · -52.7% ROE $0.19 Book/Sh · -68.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABVC
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Farm Products Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABVC (4) vs AQB (2)
Institutional Metric ABVC AQB Criterion Row Edge
Market Capitalization
Scale
$24.8M $9.7M Larger Scale ABVC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+104.5% -93.5% Higher Growth ABVC
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-52.7% -68.9% Higher ROE ABVC
52-Week Range Position
Momentum
10% ($1–$3) 11% ($1–$2) Stronger Trend AQB
Beta / 30D Volatility
Risk Regime
1.34β · 53% Vol 0.93β · 117% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
34.2 / 100 (SELL) 44.6 / 100 (HOLD) Higher Composite AQB
Trailing 12M Revenue (USD)
Operating Scale
$797,916 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.8M EBITDA ($0.49 Book/Sh · -52.7% ROE) -$7.2M ($0.19 Book/Sh · -68.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABVC +24.67 pp
ABVC: +3.3% · AQB: -21.37%
3M Horizon ABVC +38.89 pp
ABVC: +0.38% · AQB: -38.51%
6M Horizon ABVC +6.82 pp
ABVC: -14.55% · AQB: -21.37%
1Y Horizon AQB +44.24 pp
ABVC: -67.81% · AQB: -23.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs AQB. Trailing 12-month operating profitability (ABVC 0.0% vs AQB 0.0%) and valuation multiples (ABVC N/M vs AQB N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M
AQB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-68.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AQB BREAKDOWN
69d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AQB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $24.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AQB Moat Profile Cyclical / Execution-Driven Positioning
Farm Products Operator
Competes within the Farm Products value chain with $9.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABVC vs AQB Key Questions & Quantitative Answers

As of Nov 17, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over AquaBounty Technologies, Inc. (AQB) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABVC carries a Unified Composite Score of 34.2/100 (SELL) at $0.94 (N/M Forward P/E, 0.0% operating margin), whereas AQB carries 44.6/100 (HOLD) at $0.82 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AQB currently prints a higher short-term Unified Composite Score (44.6/100 HOLD vs. ABVC 34.2/100 SELL), ABVC captures the overall institutional head-to-head verdict (4–2 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+104.5% vs. -93.5% YoY). Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 43.3); meanwhile AQB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABVC leads the Growth & Scale pillar: ABVC posts +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin), compared with AQB at -93.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABVC generates $797,916 in USD-normalized revenue versus N/A for AQB. In operating R&D and SG&A reinvestment, ABVC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AQB.

ABVC screens cheaper on headline valuation multiples. ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 31.1x EV/Revenue (unreported EBITDA margin), whereas AQB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABVC (-52.7% ROE) versus AQB (-68.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 53% Vol realized risk). By comparison, AQB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.93β · 117% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.